Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan

• DOI: 10.1007/s40121-024-00968-5
• Publication Date: 2024-04-28T16:01:12Z
• Authors: Chun-Chi Yang; Chung-Feng Huang; Te-Sheng Chang; Ching-Chu Lo; Chao-Hung Hung; Chien-Wei Huang; Lee-Won Chong; Pin-Nan Cheng; Ming-Lun Yeh; Cheng-Yuan Peng; Chien-Yu Cheng; Jee-Fu Huang; Ming-Jong Bair; Chih-Lang Lin; Chi-Chieh Yang; Szu-Jen Wang; Tsai-Yuan Hsieh; Tzong-Hsi Lee; Pei-Lun Lee; Wen-Chih Wu; Chih-Lin Lin; Wei-Wen Su; Sheng-Shun Yang; Chia-Chi Wang; Jui-Ting Hu; Lein-Ray Mo; Chun-Ting Chen; Yi-Hsiang Huang; Chun-Chao Chang; Chia-Sheng Huang; Guei-Ying Chen; Chien-Neng Kao; Chi-Ming Tai; Chun-Jen Liu; Mei-Hsuan Lee; Hsing-Tao Kuo; Pei-Chien Tsai; Chia-Yen Dai; Jia-Horng Kao; Han-Chieh Lin; Wang-Long Chuang; Kuo-Chih Tseng; Chi-Yi Chen; Ming-Lung Yu
• Keywords: Hepatitis C

Eight-week glecaprevir/pibrentasvir (GLE/PIB) is indicated for treatment-naïve (TN) patients with chronic hepatitis C (CHC), or without compensated cirrhosis. Given that the Taiwanese government committed to eliminating virus (HCV) by 2025, this study aimed measure real-world evidence TN using 8-week GLE/PIB in Taiwan HCV Registry (TACR). The data of CHC treated were retrieved from TACR, a nationwide registry program organized Association Study Liver (TASL). Treatment efficacy, defined as sustained virologic response at posttreatment week 12 (SVR12), was assessed modified intention-to-treat (mITT) population, which excluded who lost follow-up lacked SVR12 data. safety profile ITT population assessed. A total 7246 (6897 cirrhosis; 349 cirrhosis) received least one dose (ITT), 7204 whom had available (mITT). overall rate 98.9% (7122/7204) among all patients, (6780/6856) and 98.3% (342/348) cirrhosis, respectively. For selected subgroups, included genotype 3 infection, diabetes, kidney disease, people injected drugs, those human immunodeficiency coinfection, rates 95.1% (272/286), (1084/1096), 99.0% (1171/1183), 97.4% (566/581), 96.1% (248/258), Overall, 14.1% (1021/7246) experienced adverse events (AEs). Twenty-two (0.3%) serious AEs, 15 (0.2%) resulted permanent drug discontinuation. Only event considered treatment related. therapy effective well tolerated regardless cirrhosis status.